Long-term efficacy of infliximab in hidradenitis suppurativa

Paradela, Sabela; Rodríguez-Lojo, Romina; Fernández‐Torres, Rosa; Arévalo, Pilar; Fonseca, Eduardo

doi:10.3109/09546634.2012.683767

Cited by 40 publications

(32 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even though an improvement is often reported in the inflammatory lesions during infliximab therapy, recurrence is also high during therapy. Up to 50 % develop new lesions after a treatment period of 37 weeks [69][70][71]. Moriatry et al [71] suggested that an 8-week interval is too long for HS patients and that a 4-week interval is more effective [71], because most patients report a gradual increase in inflammatory lesions around 6 weeks after infusion.…”

Section: Infliximabmentioning

confidence: 99%

“…It binds to the soluble and transmembrane forms of TNF-a, inhibiting TNF-a from binding to its receptors [68]. Multiple studies have reported on the efficacy of infliximab in patients with HS [69][70][71]. Mostly the same dose is given as in psoriasis, with 5 mg/kg infliximab at weeks 0, 2, and 6, and continued every 8 weeks thereafter [3,72].…”

Section: Infliximabmentioning

confidence: 99%

See 1 more Smart Citation

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Deckers

Prens

2015

Drugs

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent inflammatory nodules mostly located in the armpits and groin. Over the years multiple treatments for HS have been proposed; however, to date a cure is still lacking. In this update we provide an overview of most drug treatments reported on for HS, where possible with their mode of action and side effects. In mild cases, clindamycin lotion or resorcinol cream have proven effective. Tetracyclines are a first-line systemic option in more widespread or severe cases, followed by the combination of clindamycin and rifampicin. However, the recurrence rate is high after discontinuation of clindamycin plus rifampicin combination therapy. Long-term treatment with retinoids, especially acitretin is feasible, although teratogenicity has to be taken into account in females of reproductive age. Multiple antiinflammatory drugs have been suggested for HS, such as dapsone, fumarates or cyclosporine. However, their effectiveness in HS is based on small case series with varying results. If most common treatments have failed, biologics (e.g., infliximab or adalimumab) are the next step. Although not addressed in this review, surgical interventions are often needed to achieve remission. Key PointsHidradenitis suppurativa (HS) is a chronic inflammatory skin disease without a cure.Antibiotics (topical or oral) are often the first treatment option for HS.In cases of more extensive or therapy-resistant HS, biologicals (e.g., infliximab or adalimumab) are a good therapeutic option.

show abstract

Section: Infliximabmentioning

confidence: 99%

Section: Infliximabmentioning

confidence: 99%

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Deckers

Prens

2015

Drugs

View full text Add to dashboard Cite

show abstract

“…As regards infliximab, even if the first RCT phase II crossover study on 38 patients (15 treated and 28 placebo) was published in 2010 [25,] no additional phase III RCT studies have been published. A cumulative response rate of 58% (improvement ≥50% in 42 patients) has been reported in case reports with 73 patients with moderate to severe HS [107,108,109,110,111,112,113,114,115,116]. Infliximab is administered intravenously over a period of 2 h, whereas adalimumab is administered subcutaneously.…”

Section: Treatmentmentioning

confidence: 99%

Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review

Scuderi

Monfrecola

Dessy

et al. 2017

Skin Appendage Disord

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease presenting with painful nodules, abscesses, sinus tracts, and scarring primarily affecting apocrine gland-rich intertriginous areas. HS prevalence ranges from 0.05 to 1%. The central pathogenic event in HS is believed to be the occlusion of the upper part of the folliculopilosebaceous unit, leading to the rupture of the sebofollicular canal with the consequent development of perifollicular lymphohistiocytic inflammation. The HS treatment choices are influenced by disease severity and its individual subjective impact, involving both medical and surgical interventions. However, given the chronic nature of HS, its destructive impact on social, working, and daily life of patients, its management is often frustrating for both the patient and physician. Hence, prompt and effective management strategies are urgently needed and a multidisciplinary approach is advocated. Therefore, in this article, we highlighted the main features of HS (clinical aspects, epidemiology, pathogenesis, diagnostic criteria, classifications, comorbidities, and treatments), so that awareness of this disease might be heightened in primary care physicians and surgeons, who may be the first health care providers to see patients with this disease owing to its characteristic clinical presentation (inflammatory nodules, abscesses, sinus tract, etc.).

show abstract

“…As a prominent side effect, we found in the literature a case of bilateral Candida chorioretinitis in a patient with HS treated with etanercept [30]. The efficacy of infliximab in HS is consistently reported, as shown in table 4, often coinciding with Crohn's disease (cases summarized in table 4) [31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60]. In these last cases, it has been postulated that the improvement could be due to the similarity between the two diseases.…”

Section: Review and Discussionmentioning

confidence: 93%

Management of Hidradenitis Suppurativa with Biological Therapy: Report of Four Cases and Review of the Literature

et al. 2014

View full text Add to dashboard Cite

Several studies report the usefulness of different biological therapies in the management of a difficult-to-treat pathology such as hidradenitis suppurativa (HS). However, there are little data on this, which shows the great difficulty in the management of this disease. We will report herein our experience of the treatment of four complex cases of HS. We will also review previous cases published in the literature in order to further assess the results obtained with different biological drugs in terms of efficacy and safety. We conclude that, in the near future, biological therapy could become an essential tool in the management of cases of HS who have not previously responded to classical treatment.

show abstract

Long-term efficacy of infliximab in hidradenitis suppurativa

Abstract: Long-term IFX therapy might be an efficient, well-tolerated, safe option for patients with short-time evolution, severe HS. Relapse is common after 8 months of continuous treatment, especially in patients with more severe disease and in those treated with IFX in monotherapy.

Cited by 40 publications

References 38 publications

An Update on Medical Treatment Options for Hidradenitis Suppurativa

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review

Management of Hidradenitis Suppurativa with Biological Therapy: Report of Four Cases and Review of the Literature

Contact Info

Product

Resources

About